3. Umbruch 4.4..2005 - Online Pot

Index
AA-5-HT 156
absent-mindedness 23
ACEA 92
acetylcholine 96
acetylcholinesterase inhibitor 95
2-acyl-glycerol 90
β2 adrenergic receptor 202
adverse effect 258, 260
adverse event 255, 256
AEA membrane transporter (AMT)
68
ageing 75
ajulemic acid 155
alkaline phosphatase activity 203
allodynia 153, 252
Alzheimer’s disease (AD) 12, 37,
38, 59, 79, 89, 95, 101, 121, 132
AM-251 184, 188, 195
AM-281 32
AM-356 32
AM-374 156
AM-404 157
AM-630 32
AM-1241 32
AM-2233 32
γ-aminobutyric acid (GABA) 16
amphetamine 193
β-amyloid peptide 95
β-amyloid precursor protein 95
amyotrophic lateral sclerosis (ALS)
79, 89, 99–101
analgesia 150
ananda 4
Anandakanda 3
anandamide (N-arachidonoylethanolamine,
AEA) 17, 26, 67, 68,
113–115, 119, 122, 13, 156, 184,
185, 187, 189, 234, 259
265
angiogenesis 15, 170
animal models of HD 91
anorexia 12, 220
anti-cancer effect of cannabidiol 58
anti-convulsant effect of cannabidiol
13, 48
anti-emetics 184–186, 195
anti-emetic effect of cannabidiol 57
anti-emetic effect of
tetrahydrocannabinol 57
anti-inflammatory activity of
cannabidiol 55
anti-inflammatory potential of
cannabinoid agonists 86
anti-neoplastic activity of ∆ 9 -THC
166
anti-nociception and cannabidiol 55
antioxidant activity of cannabidiol
13, 54, 242
anti-proliferative effects of
cannabinoids 81
antipsychotic activity of cannabidiol
53
anti-tumour effect of cannabidiol
28, 58
ANV 184, 186, 192, 195
anxiety and cannabidiol 52
anxiety, agonists, HU210 142
anxiety, agonists, ∆ 9 -THC 142
anxiety, anandamide hydrolysis 143
anxiety, anandamide hydrolysis,
(FAAH) inhibitors 143
anxiety, antagonists (SR-141716)
142
anxiety, anxiolytic effects,
cannabidiol 141
anxiety, anxiolytic effects, monomethyl
cannabidiol 141